Shuttle Pharmaceuticals Holdings
NASDAQ: SHPHGaithersburg, US · Founded 2018 · Delaware corporation
Find your way into Shuttle Pharmaceuticals Holdings
Sign up to see every warm intro you have to Shuttle Pharmaceuticals Holdings
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Shuttle Pharmaceuticals Holdings team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Shuttle Pharmaceuticals operates Molecule.ai, an AI-driven software platform for molecular discovery and early-stage drug development. The platform helps researchers explore chemical space and evaluate molecular candidates to support decision-making in the earliest stages of drug development.
Founders & leadership
Shuttle Pharmaceuticals Holdings was founded in 2018 by Mira Jung and Anatoly Dritschilo.


Board
Reported raises · per SEC filings
Form D private placements$23.4M disclosed across 9 of 10 rounds · 1900–2026
▶$10MraisedMay 2026 · 47 investors · Other TechnologyRule 506(b)
- Ryan TrasoliniExecutive Officer
- Adam ChambersDirector
- Yuying LiangExecutive Officer
- George ScorsisDirector
- Angel LirianoDirector
- Christopher CooperExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $10M
- Sales commissions
- $1M
- Placement agents
- E.F. Hutton & Co.
- First sale
- Apr 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedNov 2025 · 1 investors · PharmaceuticalsRule 506(b)
- Christopher CooperExecutive Officer, Director
- Tyvin RichExecutive Officer
- Adam ChambersDirector
- Mira JungExecutive Officer
- Angel LirianoDirector
- Sachin PathigodaDirector
- George ScorsisDirector
- Timothy LorberExecutive Officer
- Oleh NabytDirector
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- Sales commissions
- $100K
- Placement agents
- WestPark Capital, Inc.
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.3MraisedJun 2025 · 1 investors · PharmaceuticalsRule 506(b)
- Mira JungExecutive Officer
- Tyvin RichExecutive Officer
- George ScorcisDirector
- Timothy LorberExecutive Officer
- Steven RichardsDirector
- Joseph TungDirector
- Peter DritschiloExecutive Officer
- Christopher CooperExecutive Officer
- Oleh NabytDirector
- Offering amount
- $4.3M
- Amount sold
- $4.3M
- Sales commissions
- $170K
- Placement agents
- WestPark Capital, Inc.
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$790KraisedOct 2024 · 5 investors · PharmaceuticalsRule 506(b)
- Joshua SchaferDirector
- Chris SenanayakeDirector
- Michael Vander HoekExecutive Officer
- Steven RichardsDirector
- Tyvin RichExecutive Officer
- Timothy LorberExecutive Officer
- Mira JungExecutive Officer
- Bette JacobsDirector
- Anatoly DritschiloExecutive Officer, Director
- Milton BrownDirector
- Peter DritschiloExecutive Officer
- Offering amount
- $1.3M
- Amount sold
- $790K
- Minimum investment
- $95K
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedJan 2023 · 1 investors · PharmaceuticalsRule 506(b)
- Mira JungExecutive Officer
- Milton BrownDirector
- Steven RichardsDirector
- Michael Vander HoekExecutive Officer
- Anatoly DritschiloExecutive Officer, Director
- Joshua SchaferDirector
- Chris SenanayakeDirector
- Bette JacobsDirector
- Peter DritschiloExecutive Officer
- Tyvin RichExecutive Officer
- Offering amount
- $4M
- Amount sold
- $4M
- Minimum investment
- $4M
- Sales commissions
- $320K
- Placement agents
- Boustead Securities, LLC
- First sale
- Jan 2023
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$125KraisedAug 2022 · 3 investors · PharmaceuticalsRule 506(b)
- Anatoly DritschiloExecutive Officer, Director
- Joshua SchaferDirector
- Mira JungExecutive Officer
- Steven RichardsDirector
- Michael Vander HoekExecutive Officer
- Chris SenanayakeDirector
- William AdkinsDirector
- Milton BrownExecutive Officer, Director
- Peter DritschilloExecutive Officer
- Tyvin RichExecutive Officer
- Offering amount
- $500K
- Amount sold
- $125K
- Minimum investment
- $25K
- Sales commissions
- $12.5K
- Placement agents
- Boustead Securities, LLC
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$365KraisedFeb 2022 · 11 investors · PharmaceuticalsRule 506(b)
- William AdkinsDirector
- Mira JungExecutive Officer
- Michael Vander HoekExecutive Officer
- Steven RichardsDirector
- Chris SenanayakeDirector
- Joshua SchaferDirector
- Anatoly DritschiloExecutive Officer, Director
- Milton BrownExecutive Officer, Director
- Tyvin RichExecutive Officer
- Peter DritschilloExecutive Officer
- Offering amount
- $2M
- Amount sold
- $365K
- Minimum investment
- $25K
- Sales commissions
- $36.5K
- Placement agents
- Boustead Securities, LLC
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$500KraisedJan 2022 · 2 investors · PharmaceuticalsRule 506(b)
- Steven RichardsDirector
- William AdkinsDirector
- Anatoly DritschiloExecutive Officer, Director
- Mira JungExecutive Officer
- Michael Vander HoekExecutive Officer
- Milton BrownDirector
- Peter DritschiloExecutive Officer, Director
- Josh SchaferDirector
- Chris SenanayakeDirector
- Tyvin RichExecutive Officer
- Offering amount
- $500K
- Amount sold
- $500K
- Minimum investment
- $250K
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 9
Companies working in the same space as Shuttle Pharmaceuticals Holdings.
Frequently asked questions
- What does Shuttle Pharmaceuticals Holdings do?
- Shuttle Pharmaceuticals operates Molecule.ai, an AI-driven software platform for molecular discovery and early-stage drug development. The platform helps researchers explore chemical space and evaluate molecular candidates to support decision-making in the earliest stages of drug development.
- Who founded Shuttle Pharmaceuticals Holdings?
- Shuttle Pharmaceuticals Holdings was founded by Mira Jung, Anatoly Dritschilo in 2018.
- How much funding has Shuttle Pharmaceuticals Holdings raised?
- Shuttle Pharmaceuticals Holdings has disclosed $23.4M raised across 9 of its 10 known rounds.
- Where is Shuttle Pharmaceuticals Holdings headquartered?
- Shuttle Pharmaceuticals Holdings is headquartered in Gaithersburg, US.




